Pharmacological treatment of the basic defect in cystic fibrosis

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Cystic fibrosis (CF) is an inherited disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• CFTR encodes a chloride channel crucial for epithelial cell function.
• Over 1900 CFTR mutations exist, categorized by their impact on CFTR protein function and stability.

Purpose of the Study:

• To review the current landscape of CFTR mutation classifications and their therapeutic implications.
• To highlight advancements in pharmacological treatments for specific CFTR mutation classes.
• To underscore the ongoing research efforts for mutations causing CFTR protein misfolding and degradation.

Main Methods:

• Review of existing literature on CFTR mutations and associated therapeutic strategies.
• Classification of CFTR mutations based on their functional consequences.
• Analysis of current pharmacological interventions and ongoing research for CFTR protein stabilization.

Main Results:

• Pharmacological treatments are available for stop-gain mutations (approx. 10% of CF patients) and certain channel gating mutations.
• The majority of CF patients possess mutations leading to CFTR protein misfolding and premature degradation.
• Research has identified compounds that partially restore chloride transport for these challenging mutations.

Conclusions:

• Therapeutic strategies for cystic fibrosis are mutation-specific, with significant progress in treating certain CFTR mutation types.
• Developing treatments for CFTR protein misfolding and degradation remains a critical area of research for the majority of CF patients.
• Continued investigation into novel compounds holds promise for improving chloride transport and addressing the root cause of CF in a broader patient population.